Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-Month results of the CRAF study

Transplantation

Volumn 85, Issue 9, 2008, Pages 1261-1269

  Shihab, Fuad S ^a   Waid, Thomas H ^b   Conti, David J ^c   Yang, Harold ^d   Holman, Michael J ^d   Mulloy, Laura C ^e   Henning, Alice K ^f   Holman Jr , John ^g   First, M Roy ^g  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d Harrisburg Hospital   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f EMMES CORPORATION   (United States)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Cyclosporine; Graft rejection; Renal transplantation; Tacrolimus

Indexed keywords

CREATININE; CYCLOSPORIN; TACROLIMUS;

ADULT; ANGINA PECTORIS; ANGIOPLASTY; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG SUBSTITUTION; ENDOCARDITIS; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MURMUR; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INFECTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PERICARDITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RISK ASSESSMENT; SIDE EFFECT; TACHYCARDIA; VALVULAR HEART DISEASE;

ADULT; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; SURVIVAL ANALYSIS; TACROLIMUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 43449132120     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816b4388     Document Type: Article

References (30)

1. Takemoto SK, Terasaki PI, Gjertson DW, et al. Twelve years experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343: 1078.
2. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
3. Nankivell BJ, Borrows RJ, Fung CL-S, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
4. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
5. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
6. Odland MD, Kasiske BL. Kidneys from female donors are at increased risk for chronic allograft rejection. Transplant Proc 1993; 25: 912.
7. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327: 840.
8. McLaren AJ, Fuggle SV, Welsh KI, et al. Chronic allograft failure in human renal transplantation: A multivariate risk factor analysis. Ann Surg 2000; 232: 98.
9. Matas AJ, Gillingham KJ, Payne WD, et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857.
10. Peschke B, Scheuermann EH, Geiger H, et al. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 1999; 51: 290.
11. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
12. Wissing KM, Abramowicz D, Broeders N, et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70: 464.
13. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384.
14. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
15. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
16. Wong W, Venetz JP, Tolkoff-Rubin N, et al. 2005 immunosuppressive strategies in kidney transplantation: Which role for the calcineurin inhibitors? Transplantation 2005; 80: 289.
17. Abramowicz D, del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
18. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
19. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials. BMJ 1999; 318: 1104.
20. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 73: 775.
21. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
22. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
23. Waid T; for the CRAF Study Group. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant 2005; 19: 573.
24. Solez K, Benediktsson H, Cavallo T, et al. Report of the Third Banff Conference on allograft pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 1996; 28: 441.
25. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
26. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: Results at 2 years. Transplantation 2001; 72: 245.
27. Mayer AD; for the European Tacrolimus Multicentre Renal Study Group. Chronic rejection and graft half-life: Five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002; 34: 1491.
28. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
29. Margreiter R; for the European Tacrolimus Versus Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002; 359: 741.
30. Bostom AD, Brown RS Jr, Chavers BM, et al. Prevention of post-transplant cardiovascular disease - report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491.